Cardiovascular (CV) disease (CVD) is the main cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Despite optimal glycaemic control, standard antihyperglycaemic therapy failed to impact CV events in intervention trials; therefore, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) issued a guidance to the pharmaceutical industry to specifically assess the CV outcomes and safety of new glucose-lowering drugs. Amongst them, sodium-glucose transporter 2 (SGLT2) inhibitors proved to not only provide good tolerance, few adverse effects, and good glycometabolic control, but also striking reduction in the risk of CV events. In this review, data from the main randomised controlled trials are presented, including post-hoc analyses looking into several aspects of CV protection. Moreover, the main findings from observational real-world studies to date are described, overall reassuring as regards to CV safety and efficacy of SGLT2 inhibitors. Finally, several mechanisms which might contribute to the cardioprotective effect of SGLT2 inhibition are depicted, including findings from recent mechanistic studies.
Skip Nav Destination
Article navigation
September 2018
-
Cover Image
Cover Image
A scanning electron micrograph (digitally altered and colourized, 4000× magnification) depicting a mesenchymal stem cell (orange) encapsulated in a self-assembling peptide hydrogel. In volume 132, issue 17 of Clinical Science, McFetridge et al. discuss the use of hydrogel materials to unlock the potential of stem cell therapy to treat chronic kidney disease. This image was provided by the authors and produced in collaboration with Dr Simon Crawford at the Ramaciotti Centre for Cryo-Electron Microscopy, and the Monash Teaching Resource Support Unit.
Review Article|
September 19 2018
Sodium-glucose transporter 2 inhibition and cardiovascular events in patients with diabetes: information from clinical trials and observational real-world data
Giulia Ferrannini;
1Department of Medical Sciences, Postgraduate School of Internal Medicine, University of Turin, Turin, Italy
2Cardiology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden
Correspondence: Giulia Ferrannini ([email protected])
Search for other works by this author on:
Lars Rydén
Lars Rydén
2Cardiology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
June 11 2018
Revision Received:
August 11 2018
Accepted:
August 15 2018
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© 2018 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society
2018
Clin Sci (Lond) (2018) 132 (18): 2003–2012.
Article history
Received:
June 11 2018
Revision Received:
August 11 2018
Accepted:
August 15 2018
Citation
Giulia Ferrannini, Lars Rydén; Sodium-glucose transporter 2 inhibition and cardiovascular events in patients with diabetes: information from clinical trials and observational real-world data. Clin Sci (Lond) 28 September 2018; 132 (18): 2003–2012. doi: https://doi.org/10.1042/CS20171374
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |